Share price of HCL Infosystems has fallen significantly on account of the CBI probe in case of Common Wealth
Games. An excellent opportunity to buy for long-term investors.
The recent addition of Delta Corp to the F&O segment indicates the operators intention. Small investors can buy in
cash & hold for a few months.
At a market cap of Rs.1400 crore, IVRCL appears to be a value buy opines a market veteran. Start accumulating at
further declines.
Games. An excellent opportunity to buy for long-term investors.
The recent addition of Delta Corp to the F&O segment indicates the operators intention. Small investors can buy in
cash & hold for a few months.
At a market cap of Rs.1400 crore, IVRCL appears to be a value buy opines a market veteran. Start accumulating at
further declines.
Strong tips to buy Artson Engineering a Tata Group company are being floated in the market by interested people.
Stay away from the counter as the company has posted a substantial loss for Q1FY12.
One healthcare analyst strongly recommends the shares of Amar Remedies, which is all set to post an EPS of Rs.18 in
FY12.
Panama Petrochem is expected to clock an EPS of Rs.75 in FY12.The share is likely to advance by over 50% to Rs.375 in
the medium term.
One pharma analyst strongly recommends the shares of Ajanta Pharma, which is doing extremely well and is poised
to register an EPS of Rs.58 in FY12. It is foraying into the US markets and its EPS could rise to Rs.70 in FY13.
Hind Rectifiers is expected to clock an EPS of Rs.10 in FY12. The share is going cheap and is expected to appreciate by
over 40% in three-to-six months.
An oil and gas analyst is strongly recommending the shares of Shiv Vani Oil & Gas for decent gains. The company is
expected to post an EPS of Rs.50 in FY12.
Stay away from the counter as the company has posted a substantial loss for Q1FY12.
One healthcare analyst strongly recommends the shares of Amar Remedies, which is all set to post an EPS of Rs.18 in
FY12.
Panama Petrochem is expected to clock an EPS of Rs.75 in FY12.The share is likely to advance by over 50% to Rs.375 in
the medium term.
One pharma analyst strongly recommends the shares of Ajanta Pharma, which is doing extremely well and is poised
to register an EPS of Rs.58 in FY12. It is foraying into the US markets and its EPS could rise to Rs.70 in FY13.
Hind Rectifiers is expected to clock an EPS of Rs.10 in FY12. The share is going cheap and is expected to appreciate by
over 40% in three-to-six months.
An oil and gas analyst is strongly recommending the shares of Shiv Vani Oil & Gas for decent gains. The company is
expected to post an EPS of Rs.50 in FY12.
No comments:
Post a Comment